Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative chemoradiotherapy versus radiotherapy after neoadjuvant immunochemotherapy and surgery for locally advanced intermediate-risk oral cancer
ChiCTR2600132094Phase 3Recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cisplatin in Oral Mucosal Carcinoma (2 arms), sponsored by Hunan Cancer Hospital. Primary endpoint: Two-year progression-free survival. Started Jun 2025; status: recruiting.
02
Drugs
cisplatin
03
Conditions
Oral Mucosal Carcinoma
Beyond the preview
Go deeper on ChiCTR2600132094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132094.